Companies / FibroBiologics, Inc.

FibroBiologics, Inc.

Nasdaq: FBLGCIK 1958777HOUSTON, TX

Financials

Revenue—
Net income$-18.65M
Total debt$60.0K
Cash$3.52M
Diluted EPS$-0.42
Shares outstanding6.7M

Ownership

6.7M shares outstanding · as of Jul 31, 2026
94.2%Insiders
Ownership
Insiders94.16%6,269,397
Institutions1.74%115,890
Public float4.10%272,906

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
O'Heeron PeteCEOCHIEF EXECUTIVE OFFICER · Director
89.49%5,958,147
Garcia Ruben aGeneral Counsel
2.70%180,000
Davis JasonChief Financial Officer
1.05%70,000
Khoja HamidChief Scientific Officer
0.92%61,250
Hoffman Robert E.Director
——

Institutional holders 6

View all →
HolderValue% of shares
Fund Evaluation Group, LLC$49.1K0.78%
Geode Capital Management, LLC$39.1K0.44%
Renaissance Technologies LLC$21.1K0.24%
BlackRock, Inc.$17.3K0.27%
BNP Paribas Financial Markets$87<0.01%
Royal Bank of Canada$0<0.01%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 2, 2026Davis Jason
Executive
BuyCommon Stock$29.0K+70K
70,000
1.05% of shares
low
Feb 27, 2026Garcia Ruben a
Executive
BuyCommon Stock$13.1K+40K
+28.57%
180,000
2.70% of shares
low
Mar 4, 2026Khoja Hamid
Executive
BuyCommon Stock$11.4K+30K
+96.00%
61,250
0.92% of shares
low
Mar 3, 2026O'Heeron Pete
CEO
BuyCommon Stock$7.4K+18K
+0.31%
5,942,275
89.25% of shares
low
Mar 2, 2026O'Heeron Pete
CEO
BuyCommon Stock$6.2K+17K
+0.30%
5,924,075
88.97% of shares
low
Mar 4, 2026O'Heeron Pete
CEO
BuyCommon Stock$6.0K+16K
+0.27%
5,958,147
89.49% of shares
low
Jun 23, 2026Hoffman Robert E.
Director
GrantStock Option (Right to Buy)—+31K
30,803
0.46% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
FBLGCommon StockEquity31573L204BBG01K4MB400